NCT05988203View on ClinicalTrials.gov

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

August 25, 2025

Study Completion Date

March 31, 2026

Conditions
Monkeypox
Interventions
BIOLOGICAL

BNT166a

Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.

Trial Locations (8)

37909

Alliance for Multispecialty Research, LLC, Knoxville

64114

Alliance for Multispecialty Research, LLC, Kansas City

92123

California Research Foundation, San Diego

98104

University of Washington Virology Research Clinic, Seattle

CB2 0QQ

Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge

GU2 7XP

Royal Surrey County Hospital Foundation Trust, NIHR Royal Surrey Clinical Research Facility, Guildford

SE1 7EH

Guy's and St Thomas' NHS Foundation Trust of St Thomas' Hospital, London

SO16 6YD

University Hospital Southampton, Southampton

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
lead

BioNTech SE

INDUSTRY